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Abstract
We evaluated the safety and immunogenicity of a chimeric alphavirus vaccine candidate in mice with selective immunodeficiencies. This
vaccine candidate was highly attenuated in mice with deficiencies in the B and T cell compartments, as well as in mice with deficient gamma-
interferon responsiveness. However, the level of protection varied among the strains tested. Wild type mice were protected against lethal VEEV
challenge. In contrast, alpha/beta (αβ) TCR-deficient mice developed lethal encephalitis following VEEV challenge, while mice deficient in
gamma/delta (γδ) T cells were protected. Surprisingly, the vaccine potency was diminished by 50% in animals lacking interferon-gamma receptor
alpha chain (R1)-chain and a minority of vaccinated immunoglobulin heavy chain-deficient (μMT) mice survived challenge, which suggests that
neutralizing antibody may not be absolutely required for protection. Prolonged replication of encephalitic VEEV in the brain of pre-immunized
mice is not lethal and adoptive transfer experiments indicate that CD3+ T cells are required for protection.
© 2007 Elsevier Inc. All rights reserved.Keywords: Alphavirus immunity; Recombinant vaccines; Venezuelan equine encephalitis virus; PathogenesisIntroduction
To develop safe, attenuated vaccines and drug therapies
against central nervous system (CNS)-invading viruses, it is
critical to elucidate the mechanisms of pathogen clearance, host
survival and pathogenesis resulting from viral encephalitis
mediated by emerging and biothreat zoonotic pathogens.
Several alphaviruses, namely eastern, western and Venezuelan
equine encephalitis viruses, are etiological agents of encepha-
litis and are highly lethal in humans and experimental animal
models (Weaver, 2005). Encephalitic alphaviruses are known to
replicate to high titers in mice, and invasion of the CNS occurs
rapidly in animals infected via the intranasal route leading to
acute, lethal encephalitis (Paessler et al., 2003, 2006a).⁎ Corresponding author. Fax: +1 409 747 0762.
E-mail address: slpaessl@utmb.edu (S. Paessler).
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doi:10.1016/j.virol.2007.05.041ThealphavirusVenezuelan equine encephalitis virus (VEEV),
a zoonotic pathogen with multiple subtypes, has been respon-
sible for significant morbidity and mortality during epizootic
outbreaks in equines and humans (Weaver et al., 1996). During
the most recent outbreak in South America in 1983, approxi-
mately 100,000 human cases of infection were reported with
over 300 clinical cases diagnosed (Weaver et al., 2004). The
case-fatality rate in equine species is relatively high and can
reach levels exceeding 80%, primarily due to the spread of
infection to the CNS, which results in encephalitis. In humans,
mortality rates are relatively low (b1%), but clinical signs of
neurological disease are prevalent, especially in children (de la
Monte et al., 1985; Weaver et al., 2004).
Various animal models have been used to examine the distinct
phases of infection, including the development of VEEV-
induced encephalitis. Both hamster and mouse models have
been used to understand the pathogenesis of the virus and the
host immune response as well as to evaluate vaccines (Charles et
308 S. Paessler et al. / Virology 367 (2007) 307–323al., 1995; Ryzhikov et al., 1991, 1995). Infection in the mouse by
a peripheral route of challenge exposure (subcutaneous) results
in a biphasic disease pattern, in which the virus initially
replicates in lymphoid tissue and ultimately progresses into the
CNS (Anishchenko et al., 2006; Paessler et al., 2003, 2006b),
while intranasal and intracranial challenge results in earlier CNS
penetration. Once CNS infection is established in naïve animals,
acute meningoencephalitis with neuronal cell death follows,
which is uniformly fatal (Charles et al., 1995; Ryzhikov et al.,
1991, 1995). Infection in the brain is associated with the deve-
lopment of an inflammatory response in the immunocompetent
host, with perivascular and vascular infiltration of mononuclear
cells, edema and micro-hemorrhages. The pathology associated
with infection is disseminated throughout the brain, with the
exception of a more prominent focal response in the cortex.
Immunohistochemical analysis of the distribution of viral
antigen in the CNS indicates staining in neurons and in the
neuropil, as well as in astrocytes (Anishchenko et al., 2006;
Paessler et al., 2006b).
VEEV is a potential biothreat agent; thus, vaccines to limit
infection and/or fatal encephalitis are currently under develop-
ment using a variety of approaches (Charles et al., 1997; Davis et
al., 1995; Paessler et al., 2006b). The live attenuated vaccine
strain, TC-83, was developed over four decades ago by serial
passaging of the Trinidad Donkey (TrD) VEEV strain in guinea
pigmyocytes and remains the only available vaccine for humans.
However, residual pathogenicity has been a concern with this
strain (Anishchenko et al., 2006; Jahrling and Scherer, 1973;
Paessler et al., 2006b). Recent new generation live-attenuated
vaccines that incorporate the use of alphavirus vectors to express
VEEV proteins have been shown to be both safe and effective in
protecting mice and hamsters from lethal disease (Paessler et al.,
2003, 2006a). Using a relatively rigorous challenge with the
VEEV ZPC738 strain via the intracerebral or intranasal routes,
mice were protected from lethal encephalitis following vaccina-
tion. Vaccinated mice did not develop any overt signs of disease
and had reduced levels of viral replication.Moreover, vaccinated
NIH Swiss (outbred) mice developed a strong anti-VEEV
neuroinflammatory response upon challenge with wild type
virus and had high titers of serum-neutralizing antibody
(Paessler et al., 2003, 2006a). Despite the initial characterization
of these responses in vaccinated mice protected from a challenge
dose that would be uniformly lethal in unvaccinated animals, the
precise basis of the adaptive immune response stimulated by the
Sindbis/VEEV chimera that ultimately leads to this protection
has not been fully characterized.
To evaluate (1) the safety of the recently described, live-
attenuated vaccine candidate and (2) the cellular basis of
protection following vaccination, which protects immunocom-
petent, wild type mice against acute, lethal encephalitis (Paessler
et al., 2003, 2006a), we utilized inbred mice with selective
immunodeficiencies in the T cell compartments (αβ TCR-
deficient or γδ TCR-deficient mice) (Itohara et al., 1993;
Mombaerts et al., 1992), in the B cell compartment (μMT-
deficient mice) (Kitamura et al., 1991), or in their ability to
respond to the cytokine interferon gamma (IFN-γR-deficient
mice) (Huang et al., 1993) in a series of studies. In preliminaryVEEV infection studies, these immunodeficient mouse strains
succumbed to disease between 6 and 8 days following ZPC738
infection, as did immunocompetent (wild type) mice (data not
shown). This indicates that these immunodeficient mice do not
differ significantly in their susceptibility to VEEV, and therefore,
can be used in this immunization/challenge model to examine
different immune effector mechanisms.
Interferon-γ is linked to activation of antigen-presenting
cells in the CNS and arming of effector activities of both the
innate and adaptive effector anti-viral pathways (Binder and
Griffin, 2003; Burdeinick-Kerr and Griffin, 2005; Owens et al.,
2005). Alpha-beta (αβ) T cells represent the majority of
peptide-specific T cells, whereas γδ T cells have been
hypothesized to form a link between innate and adaptive
immunity; however, many of the functions of γδ T cells are
unknown, particularly in the central nervous system (Born et al.,
2006). Protection from lethal encephalitis was dependent on the
presence of αβ T cell receptor (TCR)-bearing (CD3+) cells, but
not on γδ TCR-bearing cells. Remarkably, γδ TCR-deficient
mice were protected from lethal viral challenge by intranasal
inoculation with VEEV but a continued persistence of variants
of the ZPC738 challenge strain was found up to 28 days
following challenge. Our data unambiguously demonstrate
distinct roles for murine αβ and γδ T cells in the vaccine and
challenge response to neurovirulent VEEV.
Results
Safety of a Sindbis-VEEV vaccine candidate in mice
Chimeric virus is attenuated in mice with selective immune
deficiencies
All αβ TCR-, γδ TCR-, and μMT-deficient mice survived
vaccination and none of these animals showed any signs of
disease during a period of 14 days following vaccination. 93%
of IFN-γR-deficient mice survived vaccination; in one of the
three replicate experiments, two mice suddenly died without
any previous signs typical of VEE (anorexia and/or paralysis),
while all other animals appeared healthy throughout the
vaccination period (Fig. 1A). We were unable to recover any
infectious virus from the brains of the two animals that died and
do not know the precise cause of death. However, we have
observed that the health status of the IFN-γR-deficient mice
prior to any manipulations is not equivalent to the other
immunodeficient strains, and therefore, may explain this result.
Vaccination does not influence body temperature or white
blood cell counts
In the majority of mice, no febrile or hypothermic response to
vaccinationwas evident in daily telemetric bodymeasurement of
vaccinated animals (Fig. 1B). As a positive control for VEEV-
infection-induced changes in body temperature and leukopenia,
we infected unvaccinated γδ TCR-deficient mice with VEEV. In
these naïve mice infected with virulent VEEV (ZPC738), febrile
responses occurred on day 4 after infection andwere followed by
the development of hypothermia by day 7. Among the μMT-
deficient mice, a short period of increased body temperature
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evaluation indicated that no changes in white-blood-cell counts
occurred in vaccinated animals, while in naïve VEEV-infected
mice, leukopenia did occur on day 4 after infection (data not
shown).
Protection studies
Sindbis-VEEV vaccine candidate induces protection against
disease
Animals with selective immunodeficiencies, with the excep-
tion of IFNγR-deficient mice, did not develop any detectable
disease after vaccination indicating that this recombinant
genetics approach offers a highly attenuated vaccine candidate
in the mouse model. In addition, we previously demonstrated
that the attenuated vaccine candidate was highly immunogenic
(Paessler et al., 2006a). The ZPC738 strain of VEEV is
uniformly lethal in naive mice (NIH Swiss strain) by 7 daysafter inoculation of 2×105 plaque forming units (PFU) (10,000
lethal dose (LD)50) via intranasal (i.n.) route. In subsequent
vaccination studies utilizing the chimeric SIN/ZPC virus, mice
survive this lethal challenge regimen, unlike naïve, mock
vaccinated control mice (Paessler et al., 2006a). This prompted
us to further examine the effector mechanism(s) that this
chimeric alphavirus vaccine elicits to provide protection against
lethal encephalitis caused by VEEV.
In this study, we utilized a similar vaccination/challenge
regimen to immunize naïve parental (wild type, WT) and
immunodeficient C57BL/6 mice with chimeric alphavirus-VEE
virus (SIN/ZPC), challenged these mice with virulent VEEV (ca.
5000 LD50) and assessed survival over a 28-day period. In
addition, we evaluated the histopathology, inflammatory
response, and viral replication in the brain and peripheral tissues
(lung, liver, spleen) of vaccinated mice following ZPC738
challenge.
Survival proportions
Survival curves after two immunizations with SIN/ZPC and
subsequent VEEV challenge are presented in Fig. 2. The
proportion of αβ TCR-deficient mice that survived the 28-day
observation period (0 of 18; 2 replicates; 0%) was identical to
that of mock-vaccinated WT mice (0 of 14; 1 replicate; 0%). In
contrast, the proportion of survivors among vaccinated γδ TCR-
deficient mice was high (44 of 45; 5 independent replicates;
98%) and was significantly greater (p=0.0001) than for
vaccinated WT mice (27 of 29; 2 independent replicates;
93%). Survival of IFN-γR KO mice was reduced (17 of 28; 3
independent replicates; 61%) compared to vaccinated WT and
γδ TCR KO mice. The majority of μMT-deficient mice did not
survive challenge (3 of 23; 2 independent replicates; 13%); there
was no statistically significant difference between the survival
proportion of vaccinated μMT-deficient mice and mock
vaccinated WT mice (p=0.2748).Fig. 1. Vaccine safety studies in mice. Survival and average body temperature of
wild type and immunodeficient mice vaccinated with live-attenuated chimeric
alphavirus vaccine (SIN/ZPC). Panels A and B show the survival and average
body temperature of parental C57BL/6 (wild type, WT) and immunodeficient
mice inoculated with live-attenuated chimeric alphavirus vaccine (SIN/ZPC).
Panel C shows the average body temperature following VEEV infection of
unvaccinated mice. The total percentage of surviving mice (A) and the average
body temperature (B) of SIN/ZPC vaccinated IFNγR KO, γδ TCR KO, μMT
KO and WT mice before and after vaccination on day 0 were evaluated, as
follows. Vaccination: eleven to 18-week-old, female mice were inoculated on
day 0 and day 34 subcutaneously into the medial thigh with the chimeric SIN/
ZPC virus at a dose of 5×105 plaque forming units in a total volume of 100 μl.
Mock-vaccinated mice (indicated as “WT* unvacc”) were inoculated sub-
cutaneously with 100 μl of PBS. Virus challenge: SIN/ZPC or mock-vaccinated
mice were inoculated on day 0 intranasally with an identical dose of virulent
VEEV (ZPC738) in 40 μl of PBS and deaths were recorded. Daily telemetric
monitoring of body temperature was performed for a total period of 14 days,
beginning 2 days prior to the first vaccination on day 0. Asterisk (⁎) indicates
parental C57BL/6 mice (wild type, WT). The characteristics of the parental WT
and immunodeficient mice are described in Materials and methods (Table 1).
(C) Positive control for telemetric monitoring. The body temperature of
unvaccinated γδ TCR KO mice 2 days before (day −1 and −2) and 7 days after
(day +1 through +7) infection with virulent VEEV (ZPC738) on day 0.
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The median survival time following challenge for the
vaccinated αβ T cell deficient and vaccinated μMT mice was
similar to that of mock-vaccinated WT mice: 8, 7 and 7.5 days,
respectively); however, none of the vaccinated αβ TCR
deficient mice survived beyond 14 days post-infection (Fig.
2). IFN-γR KO mice also survived for a longer period of time,
with deaths occurring at day 9 as compared to day 5 and day 7
for mock-vaccinated wild type and αβ TCR-deficient mice,
respectively.
Level of infectious virus in organs
Virus titers were evaluated in the brain and peripheral organs
of vaccinated, challenged immunodeficient mice (Fig. 3). At
day 3 post-challenge, viral titers in the brain and peripheral
tissues of wild type vaccinated mice were uniformly low (b102
PFU/g) and at day 7 post-challenge, were undetectable, in
contrast to mock-vaccinated wild type mice, in which high titers
were detected (N105 PFU/g, Fig. 3). For animals with selective
immune deficiencies that were vaccinated, high levels of
infectious virus were detected in all tissues at either day 3 or day
7, with the highest titers in the brain at day 7 post-challenge
(Fig. 3). All the parental WT and αβ TCR-deficient mice
developed hind limb paralysis prior to death (as indicated by the
black bar in Fig. 3), which is a hallmark of disease development
in VEEV-infected mice. Statistical analysis comparing the
differences in viral titer between groups indicates that, despite
the appearance of a higher average viral titer in the liver at 3 dpi
for the γδ TCR-deficient mice, this difference is not statistically
significant (Kruskal–Wallis test, p=0.3916) (Table 1).
Histopathology and distribution of viral antigen in the brain in
response to VEEV infection in vaccinated immunodeficient and
wild type mice
We also evaluated the relative degree of inflammation,
necrosis (Fig. 4) and viral antigen level (Fig. 5) in the brains of
vaccinated, ZPC738 challenged mice at day 3 and day 7 post-
infection. Semi-quantitative analysis of the histopathology and
immunohistochemistry results is presented in Table 2. On day 3
post-infection, γδ TCR-deficient mice exhibited an inflamma-
tory response comparable to other groups of vaccinated,
immunodeficient mouse strains tested, in addition to slightly
more extensive tissue necrosis, which was comparable to that of
mock-vaccinated WT control mice. In αβ TCR-deficient mice,
the extent of inflammation and necrosis was at an intermediateFig. 2. Vaccine efficacy in the mouse model. Survival of SIN/ZPC double-vaccinated
Six-week-old, female parental C57BL/6 (wild type, WT) and immunodeficient mice
with the chimeric SIN/ZPC vaccine at a dose of 5×105 plaque forming units (PFU) in
recorded following intranasal challenge with virulent VEEV (ZPC738) at a dose of 2×
vaccination. Asterisk (⁎) indicates parental C57BL/6 mice (wild type, WT) and the c
(Table 1). (A) The total percentage of surviving mice. (B) Number of surviving mice
(Altman, 1991) indicates that there is a statistically significant difference in surviv
(logrank, pb0.0001). Fisher's exact test was used to compare the survival proportion
are indicated on the survival curve.level relative to mock vaccinated WT and vaccinated γδ TCR-
deficient mice (Table 2).
In agreement with the viral titers presented in Fig. 3, the
relative levels and localization of viral antigen in various areas
of the brain that was identified by immunohistochemistry did
not differ extensively among the treatment groups (Fig. 5,
Table 2). Early in infection (day 4 post challenge), viral
antigen was detectable in the olfactory bulb and brain stem in
all of the animals, with the exception of previously vaccinated
WT mice (Fig. 5). By day 7 post challenge, almost all of the
parts of the brain were positive for virus antigen in
immunodeficient mice and in mock vaccinated, WT mice.
Strong staining of viral antigen was detected in the hippo-
campus, the brain stem as well as in the cortex (Fig. 5) and the
cerebellum.
B- and T-cells actively migrate into VEEV-infected brains
We performed histopathology and immunohistochemistry
studies (Figs. 5–7) to determine whether a correlation existed
between the presence of viral antigen, the type of lymphocytes
entering the brain and protection of vaccinated animals. On
day 7 post-challenge, we detected histopathological encepha-
litis and focal infiltration of B220 positive (B220+) cells in αβ
TCR-deficient mice (Fig. 6A) and in γδ TCR-deficient mice
(Fig. 6B), while detecting a relatively high proportion of
B220+ cells in brains of γδ TCR-deficient mice on day 12
post-challenge (Figs. 6C–D). In contrast, immunocompetent
mice had few B220+ cells in their brains, while in μMT-
deficient mice, no B220+ cells could be detected at any time
(data not shown). In vaccinated αβ TCR-deficient mice,
encephalitis was evident in histology sections of the brains on
day 7 post-challenge (Fig. 4D), in the absence of CD3 positive
(CD3+) cells (Fig. 7C), while CD3+ cells were abundant in
brains of γδ TCR-deficient mice (Figs. 7E–F). A similar level
of CD3+ cells was demonstrable on day 12 in asymptomatic
γδ TCR-deficient mice (Figs. 7C–D), while the level was
strongly reduced on day 28 (data not shown). WT mice that
were previously vaccinated developed a relatively modest
inflammatory response (Fig. 7A), in contrast to mock-
vaccinated, encephalitic animals from which brain sections
stained intensely for CD3+ cells on day 7 post-infection (Fig.
7B).
Serum neutralizing antibody responses to vaccination and
challenge with VEEV in immunodeficient mice
The humoral immune response was assessed using plaque
reduction neutralization test (PRNT, 80% reduction) towild type and immunodeficient mice following challenge with virulent VEEV.
were vaccinated on day −42 and day −14 subcutaneously into the medial thigh
a total volume of 100 μl of PBS or with PBS alone (WT⁎ unvacc). Deaths were
105 PFU per animal (ca. 1000 LD50) in 20 μl of PBS at 6 weeks following initial
haracteristics of immunodeficient mice are described in Materials and methods
in replicate experiments. Comparison of survival curves using the logrank test
al overall between the experimental groups over the 28-day monitoring period
of each vaccinated strain to the mock vaccinated WT, and the individual p-values
Fig. 3. Vaccine efficacy in the mouse model. Mean VEEV titer in organs of SIN/ZPC vaccinated wild type and immunodeficient mice at 3 and 7 days post-challenge
with ZPC738. Mice were immunized on day −42 and day −14 with chimeric SIN/ZPC vaccine at a dose of 5×105 plaque-forming units (PFU) in 100 μl of PBS or
with PBS (WT* Mock) via subcutaneous route and challenged intranasally with 2×105 PFU of virulent VEEV (ZPC738) per animal in 20 μl of PBS. Asterisk (⁎)
indicates parental C57BL/6 mice (wild type, WT) and the characteristics of immunodeficient mice are described in Materials and methods (Table 1). Animals were
sacrificed at (A) 3 days and (B) 7 days post-challenge and organs were harvested for viral titration. The limit of detection was 40 PFU/g, as indicated by the solid line.
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of vaccinated mice (parental WT and immunodeficient) pre-
and post- challenge (Table 3). The PRNT titers of SIN/ZPC
vaccinated WT C57BL/6 mice were N80 (14/14; 100%
positive). The majority of the vaccinated γδ TCR-deficient
mice (27/33; 82% negative) did not develop detectable levels
of neutralizing antibodies by the end of the study (28 days
after challenge). Overall, the titers were slightly reduced in the
majority of the positive serum samples obtained from γδ TCR-
deficient mice relative to WT mice, and ranged from 20 to
320. Neutralizing antibody titers in αβ TCR-deficient mice (0/
20; 0% positive) were uniformly below the limit of detection
(titer b20). A minor proportion of IFN-γR KO mice
developed detectable levels of neutralizing antibodies (2/8;
25% positive).Reconstitution of protection in αβ TCR-deficient mice
To exclude the possibility that the persistence of effector
cells is responsible for this protection in γδ TCR-deficient mice,
we performed an additional experiment in which mice were
challenged 1 month after a single vaccination (Fig. 8); these
mice were fully protected from lethal outcome (15/15; 100%
survival). Further, to determine if αβ T cells directly mediate
protection, adoptive transfer experiments were performed using
VEEV-specific T cells obtained from vaccinated donor mice.
Experiments were designed to test restoration of protection by
adoptive transfer of CD3+ T cells from spleen of WT C57BL/6
donor mice vaccinated with chimeric SIN/ZPC (Figs. 8B–C).
The purity of isolated T cells, as assessed via flow cytometric
analysis of cells immunostained with CD3 antibody, was 90%
Table 1
Characteristics of immunodeficient mice
Name Strain (Stock number) a Description Reference
C57BL/6 B6 (#000664) Parental strain (wild type) (Waterston et al., 2002)
αβ TCR KO B6.129P2-Tcrbtm1Mom/J (#002118) Disruption of T-cell receptor beta (Tcrb) chain (Mombaerts et al., 1992)
Deficient in αβ T cells (CD4+CD8+ cells ~6% of wild-type)
γδ TCR KO B6.129P2-Tcrdtm1Mom/J (#002120) Disruption of T-cell receptor delta (Tcrd) chain (Itohara et al., 1993)
Deficient in γδ T cells (all adult lymphoid and epithelial organs)
μMT KO B6.129S2-Igh-6tm1Cgn/J (#002288) Disruption in immunoglobulin heavy chain-6 (Igh-6, heavy chain of IgM) (Kitamura et al., 1991)
Deficient in mature B cells
IFN-γR KO 129-Ifngr1tm1Agt/J (#002702) Disruption of interferon gamma receptor 1 (Ifngr1) (Huang et al., 1993)
Deficient in functional IFN-γR
All mice were purchased from Jackson Laboratories (Bar Harbor, Maine).
a Immunodeficient (knockout, KO) mice were developed on the C57BL/6 (B6) background, which are described as parental (wild type, WT) in the text.
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(data not shown). Transfer of CD3+ splenic T cells from
vaccinated donors into αβ TCR-deficient mice resulted in
restoration of protection from lethal encephalitis, while control
(mock) mice were not protected. This result suggests that the
primary protective cell type elicited by vaccination with the
chimeric SIN/ZPC experimental vaccine resides within the
CD3+ αβ T cell population.
Infectious VEEV is present in the brains of γδ TCR-deficient
mice
Infectious virus could be recovered from the brains of
persistently infected γδ-TCR deficient mice either via cell
culture inoculation with brain homogenates or, alternatively, by
intracranial infection of newborn mice (Aaronson et al., 1982).
The latter proved to be a more sensitive method of isolation of
live virus from the brain tissue, with 3/33 (9%) versus 9/12
(75%) positive by cell culture or by newborn mice inoculation,
respectively (Table 4). Thus, VEEV, which is considered to be a
highly cytopathic virus, and which is uniformly lethal to
susceptible (unvaccinated) mice, can persist in the brains of
infected animals without causing clinical encephalitis or
mortality up to 28 days following challenge infection.
Discussion
Safety of the chimeric alphavirus in immunodeficient mice
Chimeric alphavirus-based vaccines represent a critical
advance in vaccine development for a number of infectious
pathogens, as Sindbis replicon particles have been shown to be
safe and effective for the induction of both cell-mediated and
humoral immune responses (Davis et al., 2000). Our results in
this and previously published studies (Paessler et al., 2003,
2006a) confirm the safety of Sindbis/VEE viruses in outbred 6-
day-old and inbred adult mice (NIH Swiss and C57BL/6). The
vast majority of adult immunodeficient mice (100% survival of
αβ TCR-, γδ TCR- and μMT-deficient mice; 93% survival of
IFNγR KO mice) tested survived vaccination and did not
develop leukopenia, fever or hypothermia.
Our results challenge the prevailing paradigm that the
penetration of the CNS and high-level replication by VEEV inthe brain leads to lethal, virus-induced encephalitis in the mouse
model. The results presented here indicate that pre-immunized,
VEEV-infected animals can tolerate relatively high levels of
viral replication in the brain without apparent clinical disease,
e.g., encephalitis or paralysis, indicating that othermechanism(s)
such as the host response to the infection may, in addition, play
a pivotal role.
The role of neutralizing antibodies and IFN-γ in protection
against lethal VEEV
Previous studies have suggested that production of neutra-
lizing antibody is critical to protection from encephalitis
caused by alphaviruses (Griffin et al., 1997). This is likely due
to the potential to augment clearance of extracellular virus. In
TC-83 vaccinated mice, T helper cells (Th1-type) cells were
shown to play an important role in protection (Bennett et al.,
1998). We report here that neutralizing antibody is elicited by
vaccination with the attenuated Sindbis/VEE virus in animals
depending, in part, on loss of an adaptive immune function.
However, detectable levels of serum neutralizing antibody
are not required for survival, as demonstrated using γδ
TCR-deficient mice, IFNγR-deficient mice and μMT mice,
although neutralizing antibody promotes protection from lethal
encephalitis.
IFN-γ is an essential switch factor for IgG2a and it is
anticipated that the IgG isotype is predominantly induced as
a result of vaccination with the Sindbis/VEEV chimera
(Snapper and Paul, 1987). Prior studies in VSV have shown
that neutralization of IFN-γ reduces neutralizing IgG
antibodies (Maloy et al., 1998). In this same series of
studies, αβ TCR-deficient mice produced IgG neutralizing
antibodies as a result of compensation from γδ T cell-derived
IFN-γ. A similar mechanism may be initiated in response to
VEEV in the CNS and could account for the reduction in
neutralizing antibody in both γδ TCR-deficient mice and
IFNγR-deficient mice. A minor proportion of μMT mice
survived infection following vaccination whereas vaccinated
αβ TCR-deficient mice uniformly died. Adoptive transfer of
CD4+ T cells from vaccinated WT donor mice results in
reconstitution of protection in αβ TCR-deficient mice,
suggesting a predominant role for this cell type (S. Paessler,
unpublished observations).
Fig. 4. Vaccine efficacy in the mouse model. Histopathological analysis of brains from vaccinated mice challenged intranasally with VEEV ZPC738. Brains were
harvested frommice obtained following the vaccination and challenge experiments described in Figs. 2 and 3. The characteristics of parental C57BL/6 mice (wild type,
WT) and immunodeficient mice are described in Materials and methods (Table 1). Photomicrographs of hematoxylin and eosin-stained brains obtained on day 7 from
the following mice: (A) WT unvaccinated, (B) WT vaccinated; and the following chimeric SIN/ZPC-vaccinated immunodeficient mice: (C) μMT, (D) αβ TCR KO,
and (E) γδ TCR KO mice. (F) A higher magnification image of panel E is shown. Multifocal mononuclear cell infiltrates as well as focal necrosis and neuronal cell
death characterized through hyperangulation of hypereosinophilic neurons and loss of neuropil, are prominent in γδ TCR KO and αβ TCR KO mice. μMT KO mice
have prominent micro-hemorrhages in addition to inflammation.
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antibodies that may be produced as a result of vaccination and/or
viral challenge. Previously, it has been shown that the
prophylactic, passive transfer of non-neutralizing, monoclonal
antibody into animals infected with neuroadapted Sindbis virus,
which causes encephalitis under experimental conditions, can
prolong survival or protect mice completely (Schmaljohn et al.,
1982). However, the efficacy of different non-neutralizing
antibody described by Schmaljohn et al. correlated with the
attenuation of CNS infection that was reflected by dramatically
(100-fold to a million-fold) reduced viral titers in the brains of
infected and treated mice in comparison to infected, but
untreated mice. This led to the hypothesis that host cell infectionwas blocked via either of two alternative mechanisms: (i)
antibody-dependent cytolysis of infected cells, or (ii) hindrance
of virus budding from infected cells by binding to the viral
proteins embedded in the membranes of infected cells
(Schmaljohn et al., 1982). Similar to results from experimental
work with Sindbis virus, Hunt et al. have demonstrated the
protection of non-neutralizing antibody to the amino terminus
of E2 of Trinidad Donkey strain of VEEV, which was based on
its ability to limit virus replication in the brains of infected
mice, and, thereby, reducing the viral load in the brain (Hunt et
al., 1990, 1991). In our evaluation of the brains in this study,
the viral loads are reduced only in vaccinated WT mice, while
other strains with selective immune deficiencies are equally
Fig. 5. Vaccine efficacy in the mouse model. Immunohistochemical analysis of the brain from SIN/ZPC- or mock-vaccinated and VEEV-challenged mice. Viral antigen
in the brain. Representative photomicrographs were obtained from immunohistological analysis of brains of 6-day-old female chimeric SIN/ZPC virus- or mock-
vaccinated mice euthanized on day 7 following virulent VEEV (ZPC738) challenge infection, as described in Figs. 2 and 3. The characteristics of parental C57BL/6
mice (wild type, WT) and immunodeficient mice are described in Materials and methods (Table 1). The localization of viral antigen (reddish-brown) was demonstrated
via immunostaining of brain sections using antibody to VEEV (ATCC, cat number: VR1250AF). VEEVantibody was detected using biotinylated secondary antibody,
followed by avidin–peroxidase color development. Slides were counter-stained with Mayer's Modified Hematoxylin prior to mounting and microscopy. (A) WT
unvaccinated, (B) WT chimeric SIN/ZPC-vaccinated; and the following chimeric SIN/ZPC-vaccinated immunodeficient mice: (C) μMT, (D) αβ TCR KO mice and
(E) γδ TCR KO. Viral antigen is detected in association with neuronal cells in the brain stem (C and D), hippocampus (A) and cortex (E).
315S. Paessler et al. / Virology 367 (2007) 307–323susceptible to VEEV replication in the brain, regardless of the
outcome of infection. Based on our data, in which seroconver-
sion was measured pre- and post-challenge, we believe that the
humoral immune response was highly limited in mice with
selective immune deficiencies, while it was robust in WT mice.
Nevertheless, we can only speculate about the importance of
non-neutralizing antibody in our model and subsequent studies
may be needed to address this issue.Role of T cells in protection from lethal encephalitis
These studies demonstrate that protection, as measured by
survival of vaccinated mice relative to mock-vaccinated
controls, may not completely depend on the presence of
detectable levels of virus neutralizing antibody in the serum.
The role of virus-specific T cells was confirmed by restoration
of protection using adoptive transfer of CD3+ donor T cells
Table 2
Semi-quantitative analysis of brain pathology and viral antigen distribution in wild type and immunodeficient mice
Replicate
mice
Day 3 Day 7
Inflammation Necrosis Viral staining Inflammation Necrosis Viral staining
αβ TCR KO 1 2 2 3 4 4 4
2 2 2 3 4 4 3
γδ TCR KO 1 3 1 3 4 4 2
2 2 1 3 3 4 2
μMT KO 1 2 1 3 3 3 3
2 3 2 3 3 4 3
IFN-γR KO n.d. n.d. n.d. n.d. n.d. n.d. n.d.
WT⁎ vaccine 1 1 1 1 1 1 1
2 1 1 1 1 1 1
WT⁎ mock 1 1 1 3 4 4 3
2 2 2 3 3 4 3
Mice were immunized with chimeric SIN/ZPC virus (5×105 plaque-forming units (PFU) in 100 μl of PBS) or with PBS alone (mock) on day −42 and day −14 via
subcutaneous route and challenged on day 0 intranasally with 2×105 PFU of ZPC738 per animal in 20 μl of PBS. Animals were sacrificed at 3 and 7 days post-
challenge and organs were harvested for histopathological analysis. Histopathology scoring: 1=normal/negative, 2=1–3 focal spots, 3=disseminated, 4=most severe.
n.d., not done. Asterisk (⁎) indicates parental C57BL/6 mice (wild type, WT) and the characteristics of immunodeficient mice are described in Materials and methods
(Table 1).
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recipients. Furthermore, the relative degree of immune-
mediated inflammation in αβ TCR-versus γδ TCR-deficient
mice did not fully correlate with viral clearance. Remarkably,
vaccinated γδ TCR-deficient mice were protected from lethalFig. 6. Vaccine efficacy in the mouse model. Immunohistochemical analysis of the br
the brain. Brains were harvested from mice obtained following the vaccination and c
C57BL/6 mice (wild type, WT) and immunodeficient mice are described in Materials
cell marker, CD45R/B220 and counter-stained with Mayer's Modified Hematoxyl
CD45R/B220-positive cells (reddish-brown) in brains of chimeric SIN/ZPC-vac
immunodeficient mice are shown: (A) αβ TCR KO, 7 days post-infection (dpi), (B) γ
image of panel C.intranasal viral challenge relative to WT mice, but VEEV
persisted in the brain for up to 28 days following inoculation.
Virus clearance was not affected in WT inbred or outbred mice
or in surviving animals lacking functional IFN-γ receptor, as
demonstrated by a lack of detectable infectious virus in theain from SIN/ZPC- and mock-vaccinated and VEEV-challenged mice. B cells in
hallenge experiments described in Figs. 2 and 3. The characteristics of parental
and methods (Table 1). B cells were detected by staining with antibody to the B
in prior to mounting and microscopy, as described in Materials and methods.
cinated, virulent VEEV (ZPC738) challenged animals from the following
δ TCR KO mice, 7 dpi, (C) γδ TCR KO, 12 dpi, and (D) a higher magnification
Fig. 7. Vaccine efficacy in the mouse model. Immunohistochemical analysis of the brain from SIN/ZPC- and mock-vaccinated and VEEV-challenged mice. T cells in
the brain. Brains were harvested from mice obtained following the vaccination and challenge experiments described in Figs. 2 and 3. The characteristics of parental
C57BL/6 mice (wild type, WT) and immunodeficient mice are described in Materials and methods (Table 1). T cells were detected by staining with antibody to the T
cell marker, CD3, and counter-stained with Mayer's Modified Hematoxylin prior to mounting and microscopy, as described in Materials and methods. CD3-positive
cells (reddish-brown) are shown in the brains of the following animals: (A) WTmock-vaccinated; 7 days post-infection (dpi), (B) WTchimeric SIN/ZPC-vaccinated; 7
dpi, and for the following vaccinated immunodeficient mice: (C) αβ TCR KO at 7 dpi, (D) γδ TCR KO at 7 dpi, (E) γδ TCR KO at 12 dpi. (F) A higher magnification
image of panel E is shown.
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data demonstrate distinct differences in the vaccine and
challenge (adaptive) response to neurovirulent VEEV in αβ
vs. γδ T-cell deficient mice. Thus, while αβ TCR-bearing T
cells appear to be strictly required for protection, γδ TCR-
bearing T cells may not; it is possible that persistence is an
indirect effect of a deficit in T cell help for B cells in the latter
mice. Future studies will examine the cell types that are
responsible for protection.
The role of cytolytic CD8+ T cells in the response to
VEEV infection has not been clearly defined, as previousstudies demonstrated a significant degree of variability,
depending upon the virus and/or mouse strain tested (Jones
et al., 2003). As neurons are not highly proliferative and are
not believed to regenerate, the mechanism of viral elimina-
tion by neurons remains under intensive study, with focus
on non-lytic and lytic mechanisms of viral clearance. As
CD4+ and γδ T cells have been shown to perform redun-
dant functions, the extent of their involvement in the
immune response may be highly dependent upon which cell
type is recruited to sites of viral replication in the CNS and
the periphery.
Table 3
Production of VEEV-neutralizing antibody in wild type and immunodeficient mice
Animal strain 80% PRNT
Pre-challengea Post-challengeb
No. positive/total testedc Percent positived No. positive/total testedc Percent positived
αβ TCR KO 0/20 0% 0/0 –
γδ TCR KO 5/28 3.6% 6/33 18.2%
μMT KO NT N/A 0/3 0%
IFN-γR KO 1/3 33% 2/8 25%
WT⁎ vaccine 29/29 100% 14/14 100%
WT⁎ mock 0/0 – 0/0 –
Mice were immunized with chimeric SIN/ZPC virus (5×105 plaque-forming units (PFU) in 100 μl of PBS) or with PBS alone (mock) on day −42 and day −14 via
subcutaneous route and challenged on day 0 intranasally with 2×105 PFU of ZPC738 per animal in 20 μl of PBS (Bellavia et al.). Plaque reduction neutralization test
(PRNT) was performed at day 0a and at day 28b following challenge with VEEV ZPC738. cThe proportion of mice that tested positive at a dilution≥1:20 is reported.
dPercent positive was calculated as the percentage that tested positive at a dilution≥1:20, as for column referenced in c. For mice that did not survive challenge, 0/0 is
reported. NT, not tested; N/A, not applicable. Asterisk (⁎) indicates parental C57BL/6 mice (wild type, WT) and the characteristics of immunodeficient mice are
described in Materials and methods (Table 1).
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mice does not entirely correlate with the clearance of infectious
virus from the brain. However, protection is positively
correlated with the accumulation of cellular infiltrates in and
around the vasculature in the brain. We routinely observed
lower levels of cellular infiltrates (morphological differences in
inflammatory foci) in the brains of αβ TCR-deficient mice.
Thus, survival appears to be enhanced by increased level of
inflammation in the brain early during the course of infection.
These results support the further study of T cell subsets, e.g.,
CD4+ and CD8+ T cells, and clearance mechanisms, to enable
us to refine our understanding of the relationship between
encephalitic VEEV invasion and replication in the brain and the
clinical outcomes of vaccination/challenge studies.
γδ T cells in VEEV immunity and protection against lethal
encephalitis
A surprising result of this study was that γδ T cell deficient
mice tolerated: (i) high levels of viral replication in the first 7
days of infection (acute phase), which was indistinguishable
from those observed in unvaccinated mice that became
paralyzed and died, and (ii) lower level virus persistence over
an extended period of time (asymptomatic, persistent phase),
which was not observed in any other group. Infectious virus
persisted in the brain, despite a moderate level of inflammation
and cellular infiltration at the site of infection, which was
observed in histopathological evaluation of brain tissues. The
persistence of infectious VEEV has not heretofore been
described, although viral RNA has been detected in the brains
of mice that survived acute Sindbis virus infection (Levine and
Griffin, 1992). The nature of persistence of VEEV in these γδ T
cell deficient mice, which occurs in the absence of clinical
disease, is an interesting finding that warrants further molecular
pathogenesis studies. These results suggest the potential for a
novel role for γδ T cells in the CNS. TCR αβ-deficiency has
been shown to impact γδ T cell development (Pennington et al.,
2003). However, in our studies, γδ TCR-deficient mice survive
a lethal VEEV challenge dose.Immune effector roles of γδ T cells in other viral infections
In general, γδ TCR-deficient mice have increased suscept-
ibility to tumors and exaggerated immunopathology in bacterial
infection models (Mombaerts et al., 1993; Mukasa et al., 1995).
Functionally, IFN-γ producing γδ T cells have been shown to
play a role in the production of neutralizing antibody responses
in TCRα- and TCRβ-deficient mice to vesicular stomatitis virus
(VSV) (Maloy et al., 1998). In response to vaccination and
challenge with VEEV, the majority of γδ TCR-deficient mice
did not mount detectable neutralizing antibody responses. The
immunoregulatory potential of γδ TCR-bearing cells is diverse
with the potential to regulate cellular infiltration and retention at
sites of inflammation, positively or negatively regulate effector
T cell function including cytotoxicity, directly lyse antigen-
presenting cells and block the influx of neutrophils (Hayday and
Tigelaar, 2003). Further, in experimental models of autoimmune
encephalomyelitis, γδ T cells have been shown to promote
downmodulation of the inflammatory response by inducing
turnover of encephalitogenic T cells via a CD95L-dependent
mechanism (Ponomarev and Dittel, 2005). Interestingly, this
regulation appears to occur late in the disease process and may
involve cross-talk with αβ TCR-bearing cells. The precise basis
of the specific host–pathogen-interaction(s) responsible for
clearance of infectious virus or for selection of viral variants is
unclear, but occurs in a microenvironment of a more extensive
inflammatory and necrotic response in this particular model.
These results are in contrast to previously published role for αβ
TCR-bearing T cells in the encephalitic Sindbis virus model.
Animals deficient in αβ, but not γδ T cells had lower mortality
rates when infected with neuroadapted Sindbis virus, indicating
different contributions to the outcome of the brain infection
(Rowell and Griffin, 2002). Recent studies for orthopox virus
infections have shown a key role for γδ T cell-derived IFN-γ in
innate immunity to infection (Agrati et al., 2006). In corona-
virus infection, human Vγ9Vδ2 T cells display an interferon-
γ-dependent anti-SARS-CoV activity and are able to directly
kill SARS-CoV-infected target cells (Poccia et al., 2006).
Gamma-delta T cells also mediate demyelination in athymic
Fig. 8. Vaccine efficacy in a single immunization model and protection mediated
by passive cell transfer. (A) Six-week-old, female γδ TCR-deficient mice were
vaccinated on day −42 into the medial thigh with the chimeric SIN/ZPC vaccine
at a dose of 5×105 plaque forming units (PFU) in a total volume of 100 μl of
PBS or with PBS alone (WT⁎mock). Deaths were recorded following intranasal
challenge with virulent VEEV (ZPC738) at a dose of 2×105 PFU per animal (ca.
1000 LD50) in 20 μl of PBS at 6 weeks following initial vaccination. Asterisk (⁎)
indicates parental C57BL/6 mice (wild type, WT) and the characteristics of
immunodeficient mice are described in Materials and methods (Table 1). (B–C)
Naïve (recipient) αβ TCR-deficient mice (N=15) were injected on day −28 via
intraperitoneal route with 5×107 CD3+ Tcells (isolated as described in Materials
and methods) suspended in 100 μl of sterile phosphate-buffered saline (PBS). As
controls for reconstitution experiments, five mice were inoculated with PBS
alone. Recipient mice were immunized with chimeric SIN/ZPC 2 days after T
cell transfer and challenged with virulent VEEV (ZPC738, 2×105 PFU/animal)
at 28 days following immunization. Animals were monitored for death, as
indicated. Due to Hurricane Rita evacuation, experiment shown in 2A was
prematurely terminated at 6 days post-challenge.
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virus (Dandekar et al., 2005). This process has been shown to be
dependent on IFN-γ production. These results contrast with
alphavirus-mediated immunity to VEEV, which appears to be
partially independent of IFN-γR signaling and partially
independent of γδ T cells in early antiviral response.
Conclusions
Our data indicate that αβ TCR-bearing T cells may be
stringently required for protection; currently, additional passive
transfer studies are ongoing to further define the role of the
specific cell types in this protection. Sequencing of persistent
viruses isolated from vaccinated and challenged γδ TCR-
deficient mice has revealed several genetic changes that are
present, irrespective of the isolation method. Studies aimed at
the characterization of the genotype and phenotypes of
persistent viruses are ongoing. We believe that the observations
described herein provide the opportunity to dissect potential
intervention points and could enable us to design additional
studies to identify prognostic markers that correlate with
protection against encephalitis in vaccinated mice.
Materials and methods
Animals
The following mice used in this study (Table 1) were
purchased from Jackson Laboratories (Bar Harbor, Maine):
C57BL/6 (wild type, WT) (Waterston et al., 2002), αβ TCR
KO (strain B6.129P2-Tcrbtm1Mom/J, C57BL/6 mice deficient
in αβ T cells) (Mombaerts et al., 1992), γδ TCR KO (strainTable 4
Persistence of infectious virus in the brains of SIN/ZPC-vaccinated, VEEV-
challenged mice
Plaque positive samples
No. positive/total tested (% positive)
Cell culture a Suckling mice b
γδ TCR KO 3/33 (9%) 9/12 (75%)
αβ TCR KO N/A N/A
μMT KO 0/3 (0%) 0/3 (0%)
IFN-γR KO 0/8 (0%) 0/8 (0%)
WT (C57BL/6) vaccine 0/22 (0%) 0/9 (0%)
NIH Swiss vaccine 0/12 (0%) 0/12 (0%)
WT⁎ mock vaccine N/A N/A
C57BL/6 mice and immunodeficient strains were vaccinated with SIN/ZPC and
subsequently challenged with ZPC738, as described in Materials and methods.
NIH Swiss mice were vaccinated as described previously (Paessler et al., 2003,
2006a). Brains were harvested at 0 and 28 days post-challenge time point and
sagitally sectioned in half. After 48 h, brains were collected and plaque assay
performed, as for the vaccinated/challenged animals. The proportion of plaque
positive samples is reported. N/A, not available. Asterisk (⁎) indicates parental
C57BL/6 mice (wild type, WT) and the characteristics of immunodeficient mice
are described in Materials and methods (Table 1).
a One half of the brain was suspended in 500 μl of media and plaque assay
was performed using 50 μl of the suspension.
b Suckling mice were inoculated with 20 μl of brain suspension via
intracranial route.
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(Itohara et al., 1993), μMT (strain B6.129S2-Igh-6tm1Cgn/J,
mature B cell-deficient) (Kitamura et al., 1991) mice and
IFN-γR KO (strain 129-Ifngr1tm1Agt/J, homozygous interferon-
gamma receptor alpha chain (R1)-chain-disrupted mice) (Huang
et al., 1993). Mice and Syrian golden hamsters (Mesocricetus
auratus purchased from Harlan, Indianapolis, Indiana) were
housed in a specific pathogen-free environment for a minimum
of 7 days until immunized. Immunization studies were carried
out in ABSL-2 and challenge studies in ABSL-3. All animal
procedures were approved by the Institutional Animal Care and
Use Committee at the University of Texas Medical Branch and
carried out according to NIH guidelines.
Telemetry
For measurement of body temperature, animals were ana-
esthetized with isoflurane (5%) and implanted subcutaneously
with BMDS IPTT-300 transponders (chip), purchased from
Bio Medic Data Systems, Inc. (BMDS, Seaford, Delaware),
using a trocar needle assembly. Animals were monitored for
signs of infection or migration of transponder prior to
temperature recording. Chips were scanned using a DAS-
6007 transponder reader (BMDS). Downloading of digital
temperature data was performed in accordance with the manu-
facturer's protocol.
Generation of chimeric SIN/VEE virus
The chimeric alphavirus SIN/ZPC construct encoding the
replicative machinery from Sindbis (SIN) virus, and the
structural genes from virulent VEEV strains were described
previously (Paessler et al., 2006a). Infectious virus for
immunization of mice was obtained by electroporation of
BHK-21 cells with viral RNA transcripts obtained from SP6-
promoter driven in vitro transcription reactions utilizing SP6
RNA polymerase (Invitrogen). Virus was harvested after
development of cytopathic effects (CPE), usually at 24 h
following electroporation (Bredenbeek et al., 1993).
Immunization and challenge with virulent VEEV strain,
ZPC738
Immunization of mice
For safety studies, eleven to eighteen-week-old, female mice
were inoculated on day 0 and day 34 subcutaneously (s.c.) into
the medial thigh with the chimeric SIN/ZPC virus at a dose of
5×105 PFU in a total volume of 100 μl or intranasally with an
identical dose of virulent VEEV (ZPC738) in 40 μl of PBS or
with PBS alone (WT⁎ mock) and deaths were recorded. Daily
telemetric monitoring of body temperature was performed for a
period of 14 days beginning 2 days prior to the first vaccination
on day 0.
Immunization and challenge of mice
For efficacy studies, immunization and challenge with
virulent VEEV (ZPC738) were performed according to pre-viously established protocols, as follows. Mice were inoculated
on day −42 subcutaneously (s.c.) into the medial thigh with
chimeric SIN/ZPC virus at a dose of 5×105 plaque-forming
units (PFU) in total volume of 100 μl of PBS. All animals
received an additional booster on day −14, unless stated
differently, using the identical route and dosage as the first
immunization. Animals were bled on days 0 and 28 after initial
immunization. Serum samples were collected by centrifugation,
heat-inactivated at 56 °C for 30 min and stored at −70 °C until
serological tests were performed. At day 0 (14 days following
second immunization), mice were challenged intranasally (i.n.)
with 2×105 PFU of virulent VEEV (ZPC738) per animal in
20 μl of PBS. Mice were observed twice daily for a period of 28
days for clinical illness (anorexia and/or paralysis) and/or death.
For chimeric SIN/ZPC vaccinated mice, three animals per
experimental group were sacrificed on days 3 and 7 and the
brains and peripheral tissues (lungs, livers, spleens, and
kidneys) were collected for viral titration or for histological
examinations and immunohistochemistry staining. On day 28
post-challenge, all animals were sacrificed and organs were
collected. For mock-vaccinated animals, two (day 7) or three
(day 3) mice were sacrificed for viral titration.
Statistical analysis
Statistical analysis of survival for all groups over the 28-day
period was performed using logrank test at a significant level of
αb0.05 in GraphPad Prism (San Diego, CA). Statistical
comparison of vaccinated mice for each strain in comparison
to the mock vaccinated WT mice was performed using Fisher's
Exact Test at a significant level of αb0.05 in GraphPad® Prism.
T cell subset isolation
CD3+ T cells were isolated from immunized donor C57BL/6
mice (Lambert et al., 2005) approximately 7 days after the last
immunization with chimeric SIN/ZPC. Briefly, thirty donor
spleens were removed and single cells suspensions generated by
mechanical disruption. Splenocytes were fractionated over
Lympholyte-M according to the manufacturer's protocol
(Accurate Chemicals, Westbury, NY). The cells were washed
three times in MACS buffer (phosphate buffered saline, pH 7.4
supplemented with 0.5% bovine serum albumin (BSA), 2 mM
EDTA) and CD3+ T cells were separated by magnetic sorting-
based negative selection according to the manufacturer's
instructions (AutoMacs, Miltenyi Biotec; Auburn, CA). Purity
was confirmed by cell surface staining and flow cytometric
analysis prior to adoptive transfer.
Flow cytometric analysis
Cells (2.5–5×105/tube) were incubated for 10 min on ice in
50 μL of blocking buffer (PBS/0.5% BSA) and then incubated
for 30min with hamster anti-mouse CD3 antibody (Pharmingen,
San Jose, CA). Cells were washed and PE-Cy5-conjugated
hamster anti-mouse antibody (BD Pharmingen, San Jose, CA)
was added (1:100) and cells incubated for 30 min. Cells were
washed in FACS buffer and fixed in PBS/2% formaldehyde for
fluorescence-activated cell sorting (FACS) analysis. Acquisition
321S. Paessler et al. / Virology 367 (2007) 307–323of data was performed on a FACScan flow cytometer (Becton
Dickinson, San Jose, CA). Data were collected and analyzed
with CellQuest software (Becton Dickinson, San Jose, CA). T-
lymphocyte populations were gated based on forward and side
scatter and expression of CD3. At least 10,000 CD3+ lympho-
cytes were acquired for analysis.
Adoptive transfer
Alpha-beta TCR-deficient mice (recipients, N=15) were
injected on day −28 via intraperitoneal route with 5×107 CD3+
T cells (obtained from SIN/ZPC immunized WT C57BL/6
donors, as described in T cell subset isolation), suspended in
100 μl of sterile phosphate-buffered saline (PBS). As controls
for reconstitution experiments, five mice were inoculated with
PBS alone. Recipient mice were immunized with chimeric SIN/
ZPC 2 days after T cell transfer and challenged with virulent
VEEV (ZPC738) at 28 days following immunization, as
described in Immunization and challenge of mice.
Viral replication in the tissues
Viral replication in the brains and peripheral organs was
assessed by plaque assay. Mouse organs, e.g., brain, lungs, liver,
spleen and kidneys, were collected at 3 and 7 days post-
challenge and sagittally sectioned in half. One half of each brain
was homogenized in MEM containing 10% FBS, and a 10%
suspension was made. The organ suspension was maintained at
−80 °C until further processing. For days 3 and 7 organs, the
titer of infectious virus was calculated using a plaque assay, as
previously described (Paessler et al., 2003). For all animals that
survived challenge to 28 days, qualitative assay of infectious
virus was performed.
Histopathology. Histopathology analysis of brain sections
was performed by a neuropathologist blinded to the sample
identification and scoring was determined as indicated in Table
1. Brains were fixed in 10% buffered formalin for 48 h, and
stored in 70% ethanol for 12 h. The samples were then
embedded in paraffin, sectioned (5 μm), mounted on slides and
standard hematoxylin and eosin (H&E) staining was performed.
Viral antigen staining. Mouse VEEV-specific hyperimmune
serum (HIS) raised against Everglades virus (a member of the
VEE complex) (ATCC, cat number: VR1250AF) was applied in
a 1:200 dilution in PBS to brain sections for 60 min. Normal
mouse serum (Ig-Ready-to-Use-Kit, DakoCytomation, Cat. No.
N1698) was used as a negative control antibody on brains from
infected mice. Brain sections from age-matched, uninfected
mice were used as a negative control tissue for immunostaining.
The Histomouse-SP Kit (Zymed, Cat. No. 95-9541) was used to
detect mouse antibody on mouse tissue. Slides were counter-
stained with Mayer's Modified Hematoxylin for microscopy.
Plaque reduction neutralization test (PRNT)
The baby hamster kidney (BHK-21) cell line (kindly
provided by Dr. Paul Olivo, Washington University, St. Louis,
MO) was maintained at 37 °C in alpha minimum essential
medium supplemented with 10% fetal bovine serum (FBS) andvitamins. Plaque reduction neutralization tests (PRNT) were
performed on BHK-21 monolayers. Briefly, a stock of chimeric
SIN/ZPC virus was incubated for 1 h at 37 °C with different
dilutions of sera taken individually from infected mice.
Subsequently, cell monolayers were incubated with virus/
serum mixtures for 1 h at 37 °C, overlaid with 0.5% agarose,
maintained for 36 h at 37 °C and stained with crystal violet
(Beaty et al., 1989). The serum dilution corresponding to an
endpoint of 80% plaque reduction was determined.
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